News

We are very excited! Autem Therapeutics, one of our portfolio companies, closed a successful financing round, raising more than $10 million.

The process was led by Zentynel Frontier Investments and included the participation of other important investors.

Autem is a company whose technology combines physics, artificial intelligence, biology and medicine to create better cancer treatments.

The company has implemented a technology based on a biophysical principle known as entangled resonance. How is it produced? Through a pocket resonator that emits waves that synchronize the rate of cell division in tumors, so that the cells are more susceptible to treatments such as chemo or radiotherapy.

At Zentynel we are proud to empower companies led by a great team with world-class academic credentials, while seeking to improve the quality of life for thousands of people who currently have limited treatment options.

If you are interested in learning more about this company, please visit their web site at https://www.autemtherapeutics.com/